Novel metabolic and lipidomic biomarkers of sarcopenia
Journal of Cachexia, Sarcopenia and Muscle · 2024-10 · 15 (5) · 2175-2186
DOI: 10.1002/jcsm.13567 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 21.08.2024. Verfasst von Wei-Hsiang Hsu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Sarcopenia, Biomarkers, Lipidomics. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council of Taiwan, National Taiwan University Hospital Bei-Hu Branch, National Science and Technology Council.
Abstract (Originalsprache)
Background
The pathophysiology of sarcopenia is complex and multifactorial and has not been fully elucidated. The impact of resistance training and nutritional support (RTNS) on metabolomics and lipodomics in older adults with sarcopenia remains uncertain. This study aimed to explore potential biomarkers of sarcopenia and clinical indicators of RTNS in older sarcopenic adults.
Methods
Older individuals diagnosed with sarcopenia through routine health checkups at a community hospital were recruited for a 12‐week randomized controlled trial focusing on RTNS. Plasma metabolomic and lipidomic profiles of 45 patients with sarcopenia and 47 matched controls were analysed using 1 H‐nuclear magnetic resonance ( 1 H‐NMR) and liquid chromatography‐mass spectrometer (LC–MS).
Results
At baseline, the patient and control groups had similar age, sex, and height distribution. The patient group had significantly lower weight, BMI, grip strength, gait speed, skeletal muscle index, lean mass of both the upper and lower limbs, and lower limb bone mass. There was a significant difference in 12 metabolites between the control and patient groups. They are isoleucine (patient/control fold change [FC] = 0.86 ± 0.04, P = 0.0005), carnitine (FC = 1.05 ± 0.01, P = 0.0110), 1‐methylhistamine/3‐methylhistamine (FC = 1.24 ± 0.14, P = 0.0039), creatinine (FC = 0.71 ± 0.04, P < 0.0001), carnosine (FC = 0.71 ± 0.04, P = 0.0007), ureidopropionic acid (FC = 0.61 ± 0.10, P = 0.0107), uric acid (FC = 0.88 ± 0.03, P = 0.0083), PC (18:2/20:0) (FC = 0.69 ± 0.03, P = 0.0010), PC (20:2/18:0) (FC = 0.70 ± 0.06, P = 0.0014), PC (18:1/20:1) (FC = 0.74 ± 0.05, P = 0.0015), PI 32:1 (FC = 4.72 ± 0.17, P = 0.0006), and PI 34:3 (FC = 1.88 ± 0.13, P = 0.0003). Among them, carnitine, 1‐methylhistamine/3‐methylhistamine, creatinine, ureidopropionic acid, uric acid, PI 32:1, and PI 34:3 were first identified. Notably, PI 32:1 had highest diagnostic accuracy (0.938) for sarcopenia. 1‐Methylhistamine/3‐methylhistamine, carnosine, PC (18:2/20:0), PI 32:1, and PI 34:3 levels were not different from the control group after RTNS. These metabolites are involved in amino acid metabolism, lipid metabolism, and the PI3K‐AKT/mTOR signalling pathway through the ingenuity pathway analysis.
Conclusions
These findings provide information on metabolic changes, lipid perturbations, and the role of RTNS in patients with sarcopenia. They reveal new insights into its pathological mechanisms and potential therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan.
- Institute of Biopharmaceutical Sciences, National Yang-Ming-Chiao-Tung University, Taipei, Taiwan.
- Master Program in Clinical Genomics and Proteomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
- Department of Pharmaceutical Sciences, School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
- Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital, Bei-Hu Branch, Taipei, Taiwan.
- Department of Physical Medicine and Rehabilitation, National Taiwan University College of Medicine, Taipei, Taiwan.
ORCID-Profile: Yun-Lian Lin
Förderung
- National Science and Technology Council of Taiwan
- National Taiwan University Hospital Bei-Hu Branch
- National Science and Technology Council
Zitieren
APA
Hsu, W. H., Wang, S. Y., Chao, Y. M., Chang, K. V., Han, D. S., & Lin, Y. L. (2024). Novel metabolic and lipidomic biomarkers of sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 15(5), 2175-2186. https://doi.org/10.1002/jcsm.13567
Vancouver
Hsu WH, Wang SY, Chao YM, Chang KV, Han DS, Lin YL. Novel metabolic and lipidomic biomarkers of sarcopenia. Journal of Cachexia, Sarcopenia and Muscle. 2024;15(5):2175-2186. doi:10.1002/jcsm.13567
BibTeX
@article{Hsu2024,
author = {Hsu, Wei-Hsiang and Wang, San-Yuan and Chao, Yen-Ming and Chang, Ke-Vin and Han, Der-Sheng and Lin, Yun-Lian},
title = {Novel metabolic and lipidomic biomarkers of sarcopenia},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2024},
volume = {15},
number = {5},
pages = {2175--2186},
doi = {10.1002/jcsm.13567}
}
EUVIMED